Issue link: http://osercommunicationsgroup.uberflip.com/i/365680
C h a i n D ru g s to re D a i l y 4 7 S u n d a y, Au g u s t 2 4 , 2 0 1 4 filed with the U.S. FDA awaiting approval, and 141 in development. Chosen by distinguished scientists at our six corporate R&D facilities in N.Y., N.J. and India, these products represent a wide range of therapeutic areas and dosage forms. Our portfolio contains many high-barrier-to-entry and difficult- to-formulate products in addition to high- volume commodity medicines. At the heart of Amneal's product development strategy is our rigorous product selection process. We leverage multidisciplinary expertise to create a well-balanced pipeline. Our product selection team keenly understands the market landscape and associated trends, which leads to timely identification of appropriate opportunities. The process is further refined by in-house team collabo- ration as well as through candid and crit- ical feedback from customers, vendors and institutional partners. CDD: What therapeutic areas does the company address? CP: Amneal's 76 FDA-approved gener- ics and additional pipeline products cover multiple therapeutic categories, including cardiovascular, central nervous system/pain, oncology, inflammation, anti-infectives, dermatology, endocrinol- ogy, diabetes, rhinology, urology, hema- tology, ophthalmic and women's health. Some areas have not previously seen much generic penetration due to specific dosage requirements, complex formula- tions or regulatory processes. By making generics available in these categories, Amneal will provide significant value to patients, physicians and the healthcare system as a whole. CDD: What dosage forms does Amneal produce, and what can customers expect Amneal ( Cont'd. from p. 1) in the future? CP: Amneal has invested in R&D and manufacturing capabilities across almost the entire range of dosage forms in the market. We have strong development programs for mainstream oral solids and liquids plus differentiated generics such as injectables, topicals, transdermals, inhalers, nasal sprays, ophthalmics and otics. CDD: How does product diversification contribute to competitive advantage? CP: The newer complex dosage forms offer unique opportunities for generics. These high-value products involve sub- stantial barriers-to-entry from a techni- cal, regulatory or commercial perspec- tive. Some of Amneal's core strengths are the capacity to handle: difficult formula- tions and high variability; products based on advanced platform technology; dosage forms that are sensitive to pro- cessing techniques and require scale-up expertise for manufacturing success; products which need immune response or clinical endpoint studies in addition to bioequivalence studies, especially those with challenging requirements; sophisti- cated device-driven products; and dosage forms requiring specialized equipment training and multi-disciplinary expertise in pharmaceuticals, chemical engineering and clinical sciences. Our strategic expansion into high- value, differentiated generics, together with our dedication to quality across all operations and total commitment to cus- tomers, partners and employees, have made Amneal one of the fastest-growing generics suppliers in the United States. For more information, visit Amneal at booth 916, go to www.amneal.com or call 866-525-7270. AMERICANS COMFORTABLE WITH GENERIC, AUTHORIZED GENERIC PRESCRIPTION PRODUCTS Data from a May 2014 survey showed that 95 percent of Americans know what a generic prescription product is – and more than 92 percent of Americans are comfortable using generic prescrip- tion drugs, up from 87 percent in 2005. The survey was conducted for Prasco Laboratories by GfK Custom Research North America, a Princeton, N.J., firm. Administered May 2-4, the online probability survey had 1025 participants, 519 males and 506 females; all participants were adults over 18. Demographic information on age, income and geography were col- lected and used in stratifying survey results. All completed surveys were weighted to make the results generaliz- able to the entire population of the United States, with margin of error on the weighted data at +/- 3 percent. In 2005, a similar, phone-based survey was conducted for Prasco. "Although we are not necessarily surprised that Americans are very aware of and increasingly comfortable with using generic drugs, we are cer- tainly pleased by this data," said Prasco's Founder and Chairman, E. Thomas Arington. "And we are even more pleased by the data pertaining to Authorized Generics, as Prasco has introduced more Authorized Generics to the marketplace than any other company." The GfK survey showed that com- pared to nine years ago, twice as many Americans are more comfortable know- ing that a generic drug is an Authorized Generic (AG). Nearly 9-out-of-10 Americans (86 percent) want the option of taking of AG, and nearly 9-out-of-10 (87 percent) would like to be told by their phar- macist when an AG is available. F u r t h e r m o r e , almost 3/4 of partici- pants (74 percent) indi- cated that they would be more comfortable taking an Authorized Generic than a standard generic, and 83 percent of respondents stated that they would choose an Authorized Generic over a standard generic at the same price point. Survey participants age 35 and older were even more receptive to Authorized Generics than was the entire sample. For participants 35 and up, 90 percent would like the option of taking an AG; 90 percent would like to be told by pharmacists when an AG was avail- able; 77 percent would be more com- fortable taking an AG than a standard generic; and 86 percent would choose an AG over a standard generic at the same price point. That survey participants 35 and older favored Authorized Generics more than those under 35 is telling, because according to a 2013 U.S. Department of Health and Human Services (HHS) publi- cation, more Americans take prescription drugs as they age. For example, HHS data col- lected from 2007-2010 showed that 90 percent of Americans age 65 and older used at least one pre- scription in a 30-day period as com- pared to only 24 percent of Americans age 17 and younger. "Prasco feels as strongly about the value of Authorized Generics now as we did in 2005. And it seems that more Americans are recognizing this value as well," added Arington. "Consumers deserve an affordable option that is identical to the brand product in every way: they deserve Authorized Generic products." For more information about Prasco Authorized Generics, visit booth 716 or Prasco's website at www.prasco.com.